Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

NCT ID: NCT01985919

Last Updated: 2025-07-15

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 150 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2010-02-01
• Study Completion Date: 2026-05-07

Brief Summary

This clinical research protocol is intended to allow for bone marrow aspirate/biopsy and blood specimens to be collected for research purposes, specifically allowing subjects the option of sedation during the bone marrow procedure. Samples will be banked for future research related to cancer and other diseases. Researchers hope this protocol will improve the collection of research correlative and translational biopsy specimens for clinical research.

Conditions

No Restrictions on Diagnosis

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Bone marrow aspirate/biopsy and blood specimens

Collection of blood and bone marrow specimens for research purposes and increase the successful acquisition of correlative bone marrow samples to improve translational research in bone marrow diseases

Obtaining human tissue for basic research or biospecimen bank

Intervention Type: OTHER

Interventions

Obtaining human tissue for basic research or biospecimen bank

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Planned procedure including a bone marrow aspirate and/or bone marrow biopsy
• The procedure is planned for the purpose of obtaining a research specimen (as part of another research study or as part of this stand-alone sample collection protocol.). Procedures with a dual purpose (i.e. to obtain both clinically-indicated specimens and research specimens) are permitted, but procedures to obtain clinical specimens only are not permitted.
• All subjects must provide written informed consent for the biopsy procedure, the collection of bone marrow and blood specimens for research purposes and (if planned) the administration of sedation.

Exclusion Criteria

• Moderate sedation may not be administrated to subjects with a clinical contraindication to its provision, or if the investigator believes that administration of moderate sedation would constitute under risk to the subject.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abramson Cancer Center at Penn Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dan Vogl, MD

Role: PRINCIPAL_INVESTIGATOR

Abramson Cancer Center

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Dan Vogl, MD

Role: CONTACT

PennCancerTrials@emergingmed.com

855-216-0098

Facility Contacts

Dan Vogl, MD

Role: primary

PennCancerTrials@emergingmed.com

855-216-0098

Other Identifiers

UPCC 01709

Identifier Type: -

Identifier Source: org_study_id